Published in final edited form as:

Innate Immun. 2012 ; 18(3): 373–389. doi:10.1177/1753425911411595.

A novel post-exposure medical countermeasure L-97-1 improves survival and acute lung injury following intratracheal infection with *Yersinia pestis*

Constance N Wilson¹, Constance O Vance¹, Timothy M Doyle², David S Brink², George M Matuschak², and Andrew J Lechner²

¹Endacea Inc., Research Triangle Park, NC, USA.

²Saint Louis University School of Medicine, St. Louis, MO, USA.

Abstract

Yersinia pestis, a Gram-negative bacillus causing plague and Centers for Disease Control and Prevention (CDC) classified Category A pathogen, has high potential as a bioweapon. Lipopolysaccharide, a virulence factor for *Y. pestis*, binds to and activates A₁ adenosine receptor (AR)s and, in animals, A₁AR antagonists block induced acute lung injury (ALI) and increase survival following cecal ligation and perforation. In this study, rats were infected intratracheally with viable *Y. pestis* [CO99 (pCD1⁺/Δpgm) 1 × 10⁸ CFU/animal] and treated daily for 3 d with ciprofloxacin (cipro), the A₁AR antagonist L-97-1, or cipro plus L-97-1 starting at 0, 6, 24, 48, or 72 h post-*Y. pestis*. At 72 h post-*Y. pestis*, cipro plus L-97-1 significantly improved 6-d survival to 60–70% vs 28% for cipro plus H₂O and 33% for untreated *Y. pestis* controls (*P* = 0.02, logrank test). Lung edema, hemorrhage and leukocyte infiltration index (LII) were evaluated histologically to produce ALI scores. Cipro plus L-97-1 significantly reduced lung edema, as well as aggregate lung injury scores vs controls or cipro plus H₂O, and LII vs controls (*P* < 0.05, Student's unpaired *t* test). These results support efficacy for L-97-1 as a post-exposure medical countermeasure, adjunctive therapy to antibiotics for *Y. pestis*.

Keywords

Yersinia pestis; plague; medical countermeasure; lipopolysaccharide; A₁ adenosine receptors

Introduction

Yersinia pestis, the causative agent of plague, is a Gram-negative bacillus classified as a Category A pathogen by the Centers for Disease Control and Prevention (CDC), reflecting its high potential as a weapon of bioterrorism. There is significant concern that *Y. pestis* may be used as a bioweapon in warfare or a terrorist attack as it is widely available, can be mass produced, can be aerosolized for widespread dissemination, may spread rapidly beyond the initial site of the attack, and is both highly contagious and lethal.^{1–5} The World Health Organization has predicted that 50 kg of aerosolized *Y. pestis* released over a city of

© The Author(s) 2011

Corresponding author: Constance N. Wilson, Chief Scientific Officer, Endacea, Inc., 2 Davis Drive (courier), P.O. Box 12076 (mail), Research Triangle Park, NC 27709-2076, USA. cwilson@endacea.com.

Conflict of interest

Constance N. Wilson is the Chief Scientific Officer of Endacea, Inc. (Research Triangle Park, NC, USA). Endacea is developing L-97-1 as an anti-sepsis therapeutic.

five million people would cause pneumonic plague in as many as 150,000 persons, of whom 36,000 would die.^{2,3} If persons exposed to the attack then fled, the outbreak could spread far beyond the initial site of dissemination. Pointedly, a government training exercise to assess reactions to an aerosolized *Y. pestis* attack found that disease would spread rapidly, with hospitals quickly overwhelmed and unable to care for sick patients.⁴ A bioterrorist attack with aerosolized *Y. pestis* may occur when there is a limited supply of first-line antibiotics in the Strategic National Stockpile (SNS), as well as logistical concerns for providing these antibiotics in a timely manner to the vicinity of a *Y. pestis* attack. Owing to the virulence of *Y. pestis*, if treatment is delayed for more than 24 h after the onset of symptoms, the mortality rate of pneumonic plague approaches 100%.^{3,5} Equally important, strains of *Y. pestis* have been isolated in the natural environment that are resistant to multiple antibiotics.⁶ Taken together, with the concern that multi-drug resistant strains of *Y. pestis* can be developed under laboratory conditions and that vaccines are not effective as post-exposure medical countermeasures (MCMs), a critical need exists for novel therapeutic strategies to expand the window of opportunity for treating patients in the event of mass casualties following an aerosolized attack with *Y. pestis*.

An important virulence factor for *Y. pestis* is LPS (endotoxin), a glycolipid moiety and primary component of its bacterial outer wall that contributes to *Y. pestis*-induced acute lung injury (ALI) and septicemia in animals.^{7,8} In the lungs, LPS causes structural changes that result in disrupted alveolar septa, interstitial and alveolar edema, inflammatory cell infiltration, microvascular congestion and frank alveolar hemorrhage.⁹ The pathology of ALI caused by an intravascular or intratracheal challenge with LPS resembles that with *Y. pestis* infection in animals and humans.^{10–12}

It was previously reported that LPS binds to and activates A₁ adenosine receptors on human pulmonary artery endothelial cells (PAECs) to induce the release of thromboxane and IL-6, immunomodulatory substances that are cytotoxic to endothelial cells.¹³ In animals, antagonists of the A₁ adenosine receptor (A₁AR) block LPS-induced ALI and increase survival following cecal ligation and puncture (CLP)-induced intraabdominal polymicrobial sepsis.^{9,14} Given the unmet medical need for safe and effective post-exposure MCMs for *Y. pestis*, it was our objective to investigate the efficacy of a promising clinical drug candidate, the A₁AR antagonist, L-97-1, in a rat model of pneumonic plague.

Materials and methods

Reagents and supplies

The *Y. pestis* strain CO99 pCD1⁺/Δpgm (hereafter CO99) used in these studies was a gift from Dr Susan C. Straley (University of Kentucky School of Medicine, Lexington, KY, USA) and was derived from the clinical isolate CO92, an *occidentalis* biotype that caused fatal pneumonic plague by feline-human aspirate transmission in 1992.^{10,15,16} This CO99 strain retains all of the chromosomal and plasmid-derived virulence factors of wild-type CO92, including a type III secretion system composed of *Yersinia* outer proteins, while lacking only the *pgm* (pigmentation) locus encoding an iron-transport siderophore.^{1,7,8,11} The A₁AR antagonist L-97-1 was synthesized by Scynexis Inc. (Research Triangle Park, NC, USA) under contract with Endace Inc. and stored in the dark as anhydrous powder at 26 °C until reconstituted daily in United States Pharmacopeia (USP)-grade water for use as described below. This sterile USP-grade water, as well as USP-grade normal saline (NS), isoflurane and sterile Na-heparin stock solution (1000 U/ml) were from Baxter Healthcare (Deerfield, IL, USA). Intermedic® polyethylene (PE-50) tubing for catheterizations, heart infusion broth (HIB), agar for bacterial culture plates and serum separation tubes were obtained from BD Biosciences (San Jose, CA, USA). USP-grade ciprofloxacin (cipro) was obtained as a 10 mg/ml IV solution (Hospira Inc., Lake Forest, IL, USA). Heparinized

hematocrit tubes were from American Hospital Supply (Miami, FL, USA) and blood gas capillary tubes from Instrumentation Labs (Lexington, MA, USA). Sterile 1 × PBS (pH 7.4) was from Lonza (Basel, Switzerland). Endotoxin-reduced BSA (pH 7) was from Intergen Company (Millipore, Billerica, MA, USA). Unless otherwise noted, all other chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA).

Bacterial growth and quantitation

For each experiment, CO99 from 80% glycerol frozen stocks was inoculated onto trypticase soy agar plates (TSA: 1% HIB, 1.5% agar, 0.2% D-galactose) and was grown for 72 h at 25 °C.^{17–19} Log-phase cultures were started by inoculating 8 ml of HIB with 5–10 white colonies of plated CO99 followed by shaking for 8 h at 25 °C. Then, 1.0 ml of the log-phase culture (OD₆₀₀ 0.2–0.4) was sub-cultured in 100 ml fresh HIB with overnight shaking at 25 °C.^{18,19} The CO99 inocula for infection were made by centrifuging these overnight stationary-phase cultures (OD₆₀₀ > 1.0) for 10 min at 8000 g and then twice washing the bacterial pellet with 1 × PBS at 25 °C and centrifuging for 10 min at 8000 g.

Preliminary studies were performed in catheterized rats, as described below, to determine the LD₅₀ for CO99. Based upon 6-d survival rates for three exposure levels of CO99 (1×10^7 , 1×10^8 , and 1×10^9 CFU/rat), a dose of 1×10^8 CFU/rat in 0.1 ml PBS was chosen for studies described here (Table 1). Thereafter, working inocula of 1×10^9 CFU/ml PBS as calibrated by OD₆₀₀ of ~1.35 were held at 25 °C until used within 20 min. Endotoxin levels in three representative inocula were determined using the PyroGene® detection system (Lonza, Walkersville, MD, USA) and the manufacturer's instructions. In each case, whole live bacterial cultures equivalent to the standard infectious inoculum were sonicated in the presence of a nonionic detergent (Triton X), centrifuged at 10,000 g (4 °C), and the resulting supernatants assayed. Results ranged between 3000 and 6000 EU per 10⁸ CFU, *i.e.* per animal.¹⁸ All inocula, arterial blood samples and lung homogenates (see below) were streak-plated in duplicate on TSA and grown for 72 h at 25 °C before final enumeration.

Rat model of pneumonic plague

All procedures for surgery, infection, monitoring and euthanizing animals were performed according to relevant Health and Human Services (HHS) and National Institutes of Health (NIH) guidelines and only after prior approval by the Saint Louis University Institutional Animal Care and Use Committee (IACUC). Male Sprague-Dawley rats (Harlan SPF, 250–350 g, Indianapolis, IN, USA) were housed in pairs upon arrival in positive-pressure isolation carrels within the animal care facility. After each of the two surgical preparations and intratracheal infection (*i.t.*) as described below, each rat had *ad libitum* access to food and water and was individually housed in a microisolator cage within a certified biosafety laboratory (BSL)-2+ laminar flow hood to prevent any cross-contamination among animals or contact between any animal and the laboratory environment.

Vascular catheterizations of the left carotid artery and right jugular vein were performed aseptically via a single 2 cm mid-ventral neck incision under 2% isoflurane/98% O₂ anesthesia as described previously.^{18–22} Sterile PE-50 catheters filled with 10 U/ml heparinized NS were tunneled subdermally to exit at a single site on the dorsal neck to permit arterial blood draws and hemodynamics, as well as IV infusions. Catheters were shielded by stainless steel sleeves and swivels (Instech Solomon, Plymouth Meeting, PA, USA) to allow rats free movement and access to food and water. In accordance with IACUC policy, each rat received one dose of buprenorphine (10 µg/kg, *s.c.*) for analgesia but no post-surgical antibiotics, and recovered overnight at room atmosphere and temperature in its cage as described above.

The following morning, and 18–24 h after vascular catheterization, each rat was re-anesthetized as described above (2% isoflurane/98% O₂) and positioned supine in a sterile surgical field. A 1.0 ml baseline carotid blood sample was obtained for the determination of arterial blood gases and quantitative culture, hematocrit and serum harvest. Each arterial sample was replaced with 3 ml of NS given by slow intra-arterial infusion. Only rats subsequently found to have normal blood gases and sterile baseline blood cultures before i.t. were included in the final data sets. Then, a parallel mid-ventral neck incision was made aseptically to expose the trachea. Each rat was infected by i.t. instillation of 1×10^8 CFU CO99 in 0.1 ml NS over 15–20 s during 5–6 normal inspirations, using a sterile 18 mm, 27-g needle directed caudally.^{18–20} To promote uniform dissemination of the inocula, one-third of each 0.1 ml inoculum was sequentially delivered with the rat in the supine, left decubitus, and right decubitus positions, while its body was inclined 20–30 cranially. Observations for the next 1–2 min after needle withdrawal confirmed that inocula did not insufflate surrounding neck tissues. Uniform distribution of bacterial suspensions by this technique also was confirmed by instilling the trachea of other rats in preliminary studies with inocula containing Evans Blue dye (15 mg/ml) and inspecting their lungs 1 h later. The time of infection was designated as $t = 0$ and then the neck incision was closed, anesthesia was withdrawn and the animal roused within its cage as described above.

Post-infection monitoring and treatment intervention groups

Animals were assessed at $t = 0, 1 \text{ h}, 3 \text{ h}, 6 \text{ h}, 24 \text{ h}, 48 \text{ h}, 72 \text{ h}, 96 \text{ h}, 120 \text{ h}$ and 144 h (6 d) or until death for survival, physical appearance, respiratory frequency (f), carotid arterial pulse rate (HR) and arterial blood pressure (AP), accompanied by 1.0 ml arterial blood draws for hematologic and microbiologic assays, again replaced with 3 ml of NS.^{18–22} Respiratory f (breaths/min) was assessed by counting chest movements for 1 min. Continuous or intermittent chart recordings of AP (mmHg) and HR (beats/min) were obtained with an MKIII Physiograph (International Biomedical, Houston, TX, USA) and small-displacement pressure transducers with independent analyses by two investigators. Mean arterial pressure (MAP) was calculated at key time points cited above as the sum of diastolic pressure plus one-third of the difference between systolic and diastolic pressures.^{18,22}

Hematocrit (%) was determined on a 30- μ l aliquot of each arterial blood sample to confirm that sequential bleedings did not reduce this value by more than 15% from $t = 1 \text{ h}$.^{18,22} Arterial blood gases (ABGs) were measured on 100- μ l aliquots using an IL-1600 Blood Gas Analyzer (Instrumentation Laboratories, Chicago, IL, USA) calibrated daily to ambient atmospheric pressures with a 1-m mercury barometer. Measured values for pH_a, PaCO₂ (mm-Hg), and PaO₂ (mmHg) were used to calculate arterial HCO₃⁻ (mM) and the alveolar-arterial (A – a) PO₂ gradient (mmHg).^{18–20} As $t = 1 \text{ h}$ represented the first arterial blood gas sample with the animals breathing room air, subsequent serial changes in each rat's PaO₂ were calculated using its own $t = 1 \text{ h}$ value as baseline control. An additional 50- μ l aliquot of each arterial sample was streak-plated for quantitative culture as described above, and the remaining portion of each arterial sample then clotted for sterile serum harvest and storage at -70°C .

Infected rats were randomly assigned to one of the following treatment groups: no interventions (infection controls); cipro (10 mg/kg, *b.i.d.* $\times$ 3 d, IV) plus a continuous infusion of pharmacy grade sterile water (H₂O) (0.5 ml/h $\times$ 8 h/d $\times$ 3 d); a continuous infusion of sterile H₂O only (0.5 ml/h $\times$ 8 h/d $\times$ 3 d); or cipro (10 mg/kg, *b.i.d.* $\times$ 3 d, IV) plus L-97-1 in sterile H₂O (1, 5, 10, or 20 mg/kg/h) as a continuous IV infusion (0.5 ml/h $\times$ 8 h/d $\times$ 3 d). Treatments with cipro plus H₂O, H₂O alone, or cipro plus L-97-1 started at $t = 0$ (immediately), 6, 24, 48, or 72 h after i.t. *Y. pestis* infection. All treatments were infused via venous catheters by calibrated infusion pumps (Harvard Apparatus, Cambridge, MA, USA). One additional group of CO99-infected rats received IV cipro as above plus L-97-1,

but with the drug delivered by oral gavage (20 mg/kg, *b.i.d.*) starting at $t = 72$ h post-infection; oral dosing was done without sedation, using gentle hand cradling and an 8-cm stainless steel 15-gauge gavage needle fitted to a 1.0 ml syringe. Once started, all treatments were continued for 3 d and the effects of these treatments on 6 d (144 h) survival and ALI were determined.

Post-mortem evaluations

In the 6 d survival studies, animals that survived 6 d (144 h) were necropsied; rats that died overnight were recorded as having survived until the previous observation period but were not necropsied. Also, in a 72 h time-killed study, infected rats that received no interventions were necropsied at 72 h. Rats were euthanized by isoflurane overdose (5%) and then underwent aseptic laparotomy and puncture of the diaphragm below the xiphoid process to allow an observed pneumothorax, followed immediately thereafter by dorsal aortic exsanguination.^{18,22}

Right lung lobes were then aseptically excised, rinsed with sterile NS, and blotted dry on sterile gauze. Lung microvascular edema was estimated as tissue wet-to-dry ratios (W/D) by weighing a standard section of the right caudal lobe before and after drying at 60 °C to a constant weight for 3 d.^{18,22} Lung quantitative cultures were performed using freshly harvested right upper lung lobes homogenized in ice cold PBS with glass tissue grinders (10 mg fresh tissue/ml PBS, pH 7.4), serially diluted in PBS, and 50–100 μ l plated as previously described.^{18–22} Lung bacterial burdens were calculated as CFU/g dry tissue. Likewise, standard segments of livers, spleens and kidneys were aseptically excised from all 6-d survivors and 72 h time-necropsied control infected animals. Using the same procedures described above for lung tissue, W/D ratios and quantitative cultures were determined for these organs.

Determination of ALI scores with histopathology

Entire left lung lobes were fixed *in situ* with phosphate-buffered 10% formalin at a transpulmonary inflation pressure of 20–22 cm H₂O for 30 min.^{21,22} Then 2–3 mm thick midsagittal slices of each lobe were immersed in buffered formalin overnight at 5°C. Paraffin-embedded serial sagittal sections (6 μ m) were stained with hematoxylin and eosin (H & E) for routine evaluation of histopathology. Using double-blind scoring methods, each H & E-stained section was evaluated at 40X, 100X and 400X using a scale of 0 (normal), 1 (mild), 2 (moderate), or 3 (severe) to grade parenchymal injuries.^{18,21} Acute lung injuries scored were: (a) interstitial and/or alveolar edema; (b) interstitial and/or alveolar hemorrhage; and, (c) interstitial and alveolar leukocytic infiltration indices (LII). For the first two injury types, the entire sagittal section was scanned at these multiple magnifications to assign a global severity index to each lung. In practice, at least ten random high-powered fields (HPFs) were assessed per sagittal section, starting at very low magnification (40X) and then magnifying these fields up to 400X, as needed, to denote a specific injury type, such as interstitial or alveolar edema or hemorrhage. For LII, a total of eleven HPFs for each lung section at 400X were independently selected by microscope stage coordinates and the median LII score of these eleven HPFs was reported. Total aggregate lung injury scores expressed as the sum of the individual lung injury scores (combined interstitial and alveolar scores) for edema, hemorrhage and LII were determined. Regions showing artifactual damage, such as pleural crushing, under-inflation, or compression atelectasis were excluded from analysis. Infected rats given no treatment were necropsied at 72 h ($n = 10$) and their lungs scored as described above. These animals served as treatment baseline controls for rats in those groups for which treatment began at 72 h post-i.t. infection and that were then necropsied at $t = 144$ h.

Determination of plasma [L-97-1]

To establish the kinetics of L-97-1 clearance from plasma in normal animals on this IV dosing regimen, 10 additional rats were catheterized aseptically as described above. The next day, they were briefly re-anesthetized as above and sham-infected with 0.1 ml of sterile NS before being randomly assigned to one of two drug infusion protocols. In each protocol, six 1-ml arterial blood samples were collected per rat to approximate the total blood drawn from infected animals in their first 72 h. Five non-infected rats received a single 8-h infusion of L-97-1 (10 mg/kg/h, i.v.) starting at $t = 0$ h; arterial blood samples to determine plasma [L-97-1] were obtained at $t = 1$ min (just after infusion of L-97-1 began), 30 min, 1 h, 2 h, 4 h and 8 h (as the drug infusion ended). Five other catheterized non-infected rats received three 8-h infusions of L-97-1 (10 mg/kg/h, IV) starting at $t = 0$ h, 24 h and 48 h, with arterial blood collected at $t = 1$ min, 8 h, 24 h, 32 h, 48 h and 56 h, to yield three pairs of 'peak and trough' samples. Each blood sample was drawn into a 3-ml syringe containing EDTA, mixed briefly by hand, and centrifuged at 5000 *g* for 5 min at 5 °C. Plasma samples were stored at -70°C until assayed for [L-97-1] by Prevalere Life Sciences (Whitesboro, NY, USA) by electrospray liquid chromatography/tandem mass spectrometry method partially validated at Prevalere.

Data presentation and statistical analysis

Values shown are group means $\pm$ standard errors (SEM). Survival curves were evaluated using Kaplan-Meier survival analysis and Mantel-Cox logrank tests for group comparisons in GraphPad Prism v. 5.0 (GraphPad Software Inc., San Diego, CA, USA). Repeatedly measured parameters [MAP, HR, (A-a)-PO₂, etc.] were evaluated in SAS version 9.2 using mixed linear model analysis for differences within and among treatment groups over time. Cross-sectional tissue parameters including W/D weight ratios were transformed by ranks before being analyzed using ANOVA. Lung injury scores determined by the criteria described above were analyzed using Student's *t* test for unpaired data. The level of significance was set at $P < 0.05$. To ensure the adequacy of sample sizes needed to achieve statistical significance among groups, group sizes of $n = 10$ rats each provided the power to detect a 20% difference in the proposed criteria at the $P < 0.05$ level when analyzed using the mixed linear model method.

Results

L-97-1 plus cipro started at 72 h post-infection improves 6-d survival vs cipro plus H₂O

In this rat model of pneumonic plague, only 33% (5 out of 15) animals survived the 6-d protocol when left untreated ('No Intervention', Figure 1, Table 2). Among rats that received 3 d of IV treatments starting $t = 24$ h after infection, cipro (10 mg/kg, b.i.d.) plus H₂O (0.5 ml/h $\times$ 8 h/d) resulted in a 6-d survival of 100% (10 out of 10) vs 30% survival (3 out of 10) for animals infused only with H₂O ($P < 0.05$) (Table 2). When 3 d of such treatments began at $t = 48$ h, the 6-d survival rates were 64% (9 out of 14) for cipro plus H₂O vs 11% (1 out of 9) for animals infused with H₂O alone ($P < 0.05$) (Table 2). Combining this b.i.d. dose of cipro with L-97-1 infusions (10 mg/kg/h $\times$ 8h/d) starting at $t = 48$ h yielded a 6-d survival rate of 55% (6 out of 11), not significantly different from cipro plus H₂O (Table 2).

Delaying the start of treatments until $t = 72$ h after infection, cipro plus H₂O resulted in a 6-d survival rate of 28% (5 out of 18), not different from either the 20% (2 out of 10) survival rate for L-97-1 alone (10 mg/kg/h $\times$ 8 h/d) or the 'No Intervention' group cited above (Table 2). However, 3 d of treating with cipro plus L-97-1 beginning at $t = 72$ h dramatically and significantly increased 6-d survival (60–70%) vs cipro plus H₂O (28%) ($P = 0.02$, logrank test) (Table 2, Figure 1). Among these 72-h delayed treatment groups, median survival times

for cipro plus L-97-1 at 1, 5, 10, or 20 mg/kg/h all increased to > 144 h vs the median survival time of 84 h for cipro plus H₂O, and 96 h after no intervention.

Given these striking results for 6-d survival among infected animals treated with cipro plus L-97-1 beginning at $t = 72$ h, additional infected animals received either cipro plus H₂O or cipro plus 10 mg/kg/h L-97-1 starting at $t = 72$ h for 3 d as above, before their catheters were sealed on day 6 and the animals monitored for an additional 22 d. Among these additional groups, we found the 28-d survival rates for cipro plus L-97-1 to be 78% (7 out of 9) vs 38% (3 out of 8) for cipro plus H₂O ($P = 0.12$, logrank test). In addition to these IV treatment groups, we determined the effect of orally administered L-97-1 (20 mg/kg, *p.o.*, *b.i.d.*) plus the same IV cipro regimen (10 mg/kg, *b.i.d.*) starting at $t = 72$ h post-infection on 6-d survival. We found that L-97-1 (20 mg/kg, *p.o.*, *b.i.d.*) improved 6-d survival to 60% (9 out of 15) vs cipro alone (28%; 5 out of 18) or no intervention (33%; 5 out of 15) (Table 2).

When only L-97-1 was administered (10 mg/kg/h $\times$ 8h/d $\times$ 3 d) starting immediately after infection at $t = 0$, the 6-d survival of 45% (5 out of 11) resembled the 40% (4 out of 10) for H₂O alone (0.5 mL/h $\times$ 8h/d $\times$ 3 d) (Table 2). Likewise, beginning the same treatments at $t = 6$ h resulted in a 6-d survival of 40% (4/10) for L-97-1 alone vs 50% (5 out of 10) for H₂O alone.

L-97-1 plus cipro started at $t = 72$ h post-intratracheal (i.t.) infection with *Y. pestis* improves lung injury scores vs cipro plus H₂O in 6-d survivors

Within 72 h of infection with 1×10^8 CO99 and without interventions, histologically verified lung edema (Table 3, Figure 2), LII (Table 4, Figure 3) and aggregate lung injury scores (Table 5, Figure 4) were all significantly increased vs infected animals in the no intervention group that survived to 6 d ($P < 0.05$). In such infected but untreated animals studied at $t = 72$ h, alveoli were filled with mixed leukocytic infiltrates of neutrophils, lymphocytes and macrophages, as well as occasional hemorrhagic foci and fibrinous extracellular exudate (Figure 5).

In agreement with 6-d survival data showing no benefit of cipro plus H₂O if started at $t = 72$ h, 3 d of cipro (10 mg/kg, *b.i.d.*, IV) plus H₂O starting at $t = 72$ h did not reduce individual lung injury scores (interstitial + alveolar edema; hemorrhage; and LII) or aggregate lung injury scores at $t = 6$ d vs the individual or aggregate lung injury scores for infected control animals receiving no treatment and necropsied at $t = 72$ h (Tables 3–5, Figures 2–4). However, 3 d of treatment with cipro plus L-97-1 started at $t = 72$ h significantly, and in some instances dose-dependently, reduced lung edema (Table 3, Figure 2), LII (Table 4, Figure 3) and aggregate lung injury scores (Table 5, Figure 4) in survivors at $t = 6$ d vs comparable lung injury scores for the untreated infection controls at $t = 72$ h ($P < 0.05$). At the higher doses of L-97-1, lung edema and aggregate lung injury scores were reduced vs comparable lung injury scores for those treated with cipro plus H₂O in survivors at $t = 6$ d ($P < 0.05$) and the individual lung injury scores and aggregate lung injury scores were reduced by approximately 50%.

These reduced lung injury scores among infected animals treated with cipro plus L-97-1 vs cipro plus H₂O or untreated infection controls are readily apparent microscopically. In representative lung tissue from an infected rat that survived to $t = 6$ d after treatment for 3 d with cipro plus H₂O starting at $t = 72$ h, the severity of alveolar and peribronchiolar edema and the amount of leukocyte-rich infiltrates (Figure 6) are hardly attenuated vs those noted for the untreated infection control (Figure 5). By contrast, in a representative lung field from an infected animal treated for 3 d with cipro plus L-97-1 (10 mg/kg/h $\times$ 8h/d) starting at $t = 72$ h, there is only slight peribronchiolar edema, while the overwhelming majority of

alveolar airspaces show no infiltrating leukocytes, extravasated erythrocytes, or fibrinous exudate (Figure 7).

Physiologic measurements: lung wet/dry (W/D) weight ratios, (alveolar– arterial) partial pressure gradients for oxygen [(A – a) PO₂], and mean arterial pressure (MAP)

Lung W/D weight ratios serve as an index of pulmonary microvascular permeability and were calculated for the 10 infected but untreated rats killed by protocol at $t = 72$ h, as well as for all untreated and treated 6-d survivors for the 72 h treated groups shown in Table 2 (Table 6). The lung W/D weight ratios among animals in the 72 h time killed group that received no treatment, 72 h no intervention group, was 4.77 ± 0.27 (mean $\pm$ SEM): a value very similar to those found in previous reports.^{20, 21} Among all survivors for the 72 h treated groups shown in Table 2, mean lung W/D ranged from 4.34 ± 0.58 to 4.97 ± 0.28 ; none of the treatment group means differed significantly from each other or from the value for the 72 h no intervention group (Table 6).

These indistinguishable lung W/D weight ratios were anticipated from similar alterations in f and in arterial blood gases measured on all animals while they breathed room air, starting at $t = 1$ h post-infection and continuing until necropsied at $t = 72$ h or 144 h. From a baseline f at $t = 1$ h across all infected animals of 83 ± 3 breaths/min, virtually every animal became tachypneic by $t = 24$ h and reached a peak rate of 109 ± 5 breaths/min by $t = 72$ h.

Thereafter, f subsided slowly among survivors toward a mean of 98 ± 4 breaths/min at $t = 144$ h, with rates not significantly different by treatments. Arterial blood gases measured at these same time points were used to calculate the (A – a) PO₂, which averaged 11 ± 3 mmHg on room air at $t = 1$ h across all groups. Among the survivors that subsequently received no intervention, the (A – a) PO₂ increased to 16.9 ± 9.5 mmHg by $t = 72$ h and to 29.8 ± 23.1 mmHg by $t = 144$ h. Among all 6-d survivors that received cipro plus either L-97-1 or H₂O starting at $t = 72$ h, their group mean (A – a) PO₂ values did not significantly differ from each other, from the value for the 144 h no intervention group, or from the value for the 72 h no intervention group (Table 6).

L-97-1 plus cipro started at 72 h post-infection improves MAP vs cipro plus H₂O in 6-d survivors

At $t = 1$ h, MAP and HR averaged 141 ± 5 mmHg and 462 ± 12 beats/min, respectively, among all 86 animals in the seven 72 h groups in Table 2 that had been infected 1 h earlier but were then resting quietly in their cages breathing room air. Over the next 71 h, MAP declined to 141 ± 8 mmHg and HR to 420 ± 11 beats/min among these animals, and were similar to values reported for the early stages of sepsis in other studies using conscious rats.^{18–21} Over the next 3 d, HR did not change appreciably, but MAP continued to decline in animals that received only cipro plus H₂O or H₂O treatments, falling to 91 ± 20 by $t = 144$ h in animals receiving no intervention ($n = 5$), and to 90 ± 18 in rats given cipro plus H₂O ($n = 5$) ($P < 0.05$ for both vs the value for the no intervention group at 72 h) (Table 6). By contrast, MAP among all 6-d survivors that received 3 d treatment with cipro plus any dose of L-97-1 starting at $t = 72$ h, were not significantly different vs their respective means for MAP at $t = 72$ h or from the mean MAP of 134 ± 26 mm Hg for untreated, infected animals at 72 h, being: 119 ± 21 mmHg for cipro plus L-97-1 (1 mg/kg) ($n = 6$), 120 ± 21 mmHg for cipro plus L-97-1 (5 mg/kg) ($n = 7$); 112 ± 19 mmHg for cipro plus L-97-1 (10 mg/kg) ($n = 5$); and 120 ± 21 mmHg for cipro plus L-97-1 (20 mg/kg) ($n = 4$) (Table 6).

Bacterial culture data in the lung and blood and systemic dissemination of *Y. pestis*

Quantitative culture of lung homogenates yielded large numbers of CO99 from all 10 infected animals that received no intervention and were necropsied at 72 h post-infection, averaging 1.3×10^7 CFU/g dry lung tissue. For 5 of the 15 infected animals that survived to

$t = 144$ h without intervention (Table 2), quantitative culture of lung homogenates yielded counts of CO99 averaging 9.2×10^4 CFU/g dry lung tissue. For the five 6-d survivors among 18 animals that received 3 d of cipro plus H₂O starting at $t = 72$ h, lung culture counts for 4 rats averaged 2.8×10^3 CFU/g dry weight, and the lungs of 1 rat were negative for *Y. pestis* by culture. Combining 3 d of L-97-1 infusions with twice-daily cipro yielded equally impressive reductions in lung culture counts, as exemplified by the group treated for 3 d with L-97-1 at 20 mg/kg/h $\times$ 8 h/d. Among the nine 6-d survivors in that group, lung culture counts of CO99 for five rats averaged 3.0×10^3 CFU/g dry weight, while the lungs of the other four rats were negative for *Y. pestis* by streak-plate culture.

Arterial blood samples were occasionally positive for CO99 by quantitative streak-plating, but this occurred too infrequently to yield statistically useful data. However, standard segments of livers, spleens, and kidneys were aseptically excised from all 6-d survivors whose treatments are described in Figure 1 and Table 2 for the 72 h treatment groups, using the same procedures for quantitative culture described for lung tissue in the 'Materials and methods'. Quantitative cultures of homogenates from livers, spleens and kidneys from all 10 infected animals that received no interventions and were necropsied at 72 h post-infection yielded large numbers of CO99 averaging 9.3×10^7 , 2.1×10^8 and 1.7×10^4 CFU/g dry tissue, respectively, supporting significant dissemination to distant organs of *Y. pestis* infection from the lung following i.t. administration. None of these three tissues was found to be negative for CO99 by culture among animals given no intervention that survived to 6 d. However, 3 d of treatment with cipro plus H₂O starting at $t = 72$ h consistently reduced *Y. pestis* counts in all three tissues, occasionally to zero. Combining L-97-1 infusions at any dose with cipro never increased the mean culture counts above those for cipro plus H₂O. Indeed, at an L-97-1 dose of 20 mg/kg/h, only one of nine livers sampled at $t = 144$ h grew any CO99, and all nine spleens were negative for CO99 by streak-plate culture.

Plasma levels of L-97-1 following IV infusions into uninfected animals

Plasma levels of L-97-1 were determined in five normal, uninfected rats throughout a single 8-h infusion of L-97-1 (10 mg/kg/h, IV), yielding an average peak concentration of 3.66×1.06 μ g/ml at the 4-h midpoint of the infusion, before declining slightly by 8 h (Table 7). Plasma [L-97-1] was also assessed in five normal, uninfected rats at the start and at the conclusion of three daily 8-h infusions of L-97-1 (10 mg/kg/h, IV) to simulate the most common drug delivery regimen described above. By this estimate of 'peak and trough' drug levels, these healthy rats had circulating [L-97-1] that never declined below 0.38 μ g/ml (trough level at 48 h prior to infusion on day 3) once the infusions had begun (Table 8).

Discussion

In this rat model of pneumonic plague induced by i.t. administration of *Y. pestis* CO99 (pCD1⁺/Δpgm), the combined treatment of cipro plus an infusion of L-97-1 significantly increased 6-d survival and reduced ALI versus cipro plus an infusion of H₂O, the vehicle for L-97-1, when administered 72 h post-*Y. pestis* i.t. infection for 3 d. Cipro plus an infusion of H₂O produced 100% survival if administered as late as 24 h following i.t. infection with *Y. pestis*. However, the 6-d survival benefit for cipro plus H₂O dropped off significantly when administered 48 h and 72 h post-i.t. infection to 64% and 28%, respectively. The addition of L-97-1 to cipro at 48 h did not significantly improve 6 d survival versus cipro plus H₂O; however, the addition of L-97-1 to cipro started at 72 h post-i.t. infection significantly improved 6 d survival and indices of ALI while preventing a significant decline in MAP versus cipro plus H₂O. These data suggest that L-97-1 has considerable promise as an effective, post-exposure MCM adjunctive therapy to antibiotics for treating individuals exposed to airborne *Y. pestis*, as could occur during a bioterrorist attack. The present results

are particularly significant in the absence of any Food and Drug Administration (FDA)-approved post-exposure MCMs for *Y. pestis*.

Lipopolysaccharide is a glycolipid-rich moiety forming the major constituent of the outer wall of Gram-negative bacteria (GNB), and is a recognized virulence factor responsible for the waves of pro-inflammatory cytokines released within 48–72 h in animal models of *Y. pestis*-induced pneumonic plague.^{6–8,10,23–25} The systemic effects of circulating LPS, whether released from proliferating bacteria in distal organs like liver and spleen after hematogenous spread from the lungs, or by antibiotic-induced lysis of bacteria, may explain the ALI, multi-system organ failure and fatal shock clinically seen with GNB infections, including *Y. pestis* pneumonia.^{6,26,27}

In the lungs, LPS causes disruption of the blood-air barrier, interstitial and alveolar edema, hemorrhage, and inflammatory cellular infiltration as noted for intrapulmonary *Y. pestis* infections in humans and animals.^{3,9–12,18,19,21,25,28–30} In animal models of pneumonic plague, histopathologic changes of ALI appeared within 48 h of inhalation and increased in severity by 72 h.^{25,29} The role of LPS in *Y. pestis* induced ALI and septic shock is supported by studies in rats made bacteremic by IV challenge with the highly attenuated *Y. pestis* strain, KIM6⁺ (plasmid-cured, pCD1⁻). In a similar manner to the rats treated with *Y. pestis* CO99 in the current study, the rats treated with KIM6⁺ developed severe lung injury characterized by hemorrhage, alveolar edema and neutrophil infiltration, and soon succumbed to fatal septic shock.^{19,30} In that same study, rats challenged IV with equivalent numbers of heat-killed KIM6⁺ still developed diffuse ALI with alveolar edema, perivascular cuffing and rapid neutrophilic infiltration; however, these animals did not progress to respiratory failure and fatal shock as a result of the self-limiting endotoxemia from nonproliferating bacteria.¹⁹ These results support the conclusion that *Y. pestis* LPS is both necessary and sufficient to initiate ALI and to sustain *Y. pestis*-induced ALI and fatal septic shock.

It is possible that in the rat model of pneumonic plague described in these studies, and as is suggested by previous reports, LPS released from bacterial foci following blood-borne dissemination to multiple organs, contributes to the histopathologic changes of ALI evident at 72 h following inhalation of *Y. pestis*. In the current study, treatment with only cipro plus H₂O that began at 24 h and 48 h following infection was effective and improved 6-d survival. However, at 72 h post-exposure to i.t. *Y. pestis*, cipro plus H₂O was not effective and increased the mortality rate versus the untreated infected controls. When administered concurrently with cipro at 48 h post-exposure, L-97-1 did not improve survival versus cipro plus H₂O. However, when administered with cipro starting 72 h post-exposure to *Y. pestis*, L-97-1 significantly increased 6-d survival. These findings suggest that the proliferation of intrapulmonary and disseminated bacteria within 72 h had reached sufficient mass to produce circulating levels of LPS that cause systemic effects. This is supported by the findings in a murine pneumonic plague model, where bacterial transcription profiles changed within the lung from day 2 to day 3 after infection with *Y. pestis*, confirming that expression of virulence factors, including LPS, increased with the duration of infection.^{31,32}

The findings from this current study are consistent with reports by others demonstrating a peak in bacterial counts in the lung and distal organs, as well as peaks in plasma cytokine levels and severity of lung injury at 72 h post-infection with *Y. pestis* CO92 via an intrapulmonary (intranasal or aerosol) route.^{10,25} It has been suggested by others that this pro-inflammatory response observed at 72 h post-infection may be due, in part, to the effects of circulating LPS.²⁴ Equally important, the reduced survival rate seen in the 72 h cipro plus H₂O treated group versus untreated, infected animals in the current study, may be caused by lysis of bacteria by cipro and the subsequent release and systemic effects of LPS. In this

setting, as an adjunctive therapy to cipro, L-97-1 may be blocking the effects of LPS, as L-97-1 did not improve survival when administered alone, either immediately ($t = 0$ h), 6 h or 72 h post-i.t. *Y. pestis* exposure.

Adenosine receptors are G protein-coupled receptors, with A₁, A_{2a}, A_{2b} and A₃ subtypes defined to date by pharmacologic and molecular biologic approaches and identified in a number of different species, including humans.³³ The A₁AR couples via a pertussis toxin-sensitive inhibitory G protein to multiple effector systems, including: adenylyl cyclase; phospholipases A₂ and C, K⁺ and Ca²⁺ channels; and guanylate cyclase.³³ Activation of A₁AR causes negative inotropic, chronotropic and dromotropic effects in the heart,^{34,35} vasoconstriction in lung³⁶ and kidney,³⁷ bronchoconstriction,³⁸ and pro-inflammatory effects for a number of different cell types, including neutrophils and macrophages.³³ In humans, plasma adenosine levels are increased in sepsis and predict negative outcomes.³⁹ While A₁ARs are normally quiescent under normal physiologic conditions, they are upregulated by hypoxia, stress, ischemia/reperfusion and inflammation, including in the heart, brain and kidney.³³ For example, TNF- α increases myocardial expression of A₁ARs, which, in turn, depress cardiac contractility and may contribute to ventricular systolic dysfunction during sepsis.³⁴ In addition, intraperitoneal administration of LPS increases expression of A₁ARs in the spleen and brain via a NF- κ B-dependent mechanism.⁴⁰

When considered together, several reports suggest that the activation of A₁ARs in the lung may contribute to LPS-induced ALI. LPS from GNB binds to and activates A₁ARs on human PAECs to induce the release of thromboxane and IL-6, substances that are cytotoxic to endothelial cells.¹³ Activation of A₁ARs on endothelial cells increases their permeability, while their activation on alveolar type 2 cells decreases lung fluid clearance, actions on both cell types that promote pulmonary edema.^{9,41–43} In one report, the high-affinity A₁AR antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) restored alveolar fluid clearance by 80%.⁴³ Thus, by blocking activation of A₁ARs, an A₁AR antagonist may provide positive inotropic support, maintain pulmonary and renal blood flows, and attenuate LPS-induced ALI.

Support that the A₁AR is an important molecular target for LPS comes from both *in vivo* and *in vitro* studies. It was reported previously that selective A₁AR antagonists similar to L-97-1 block LPS-induced ALI in animals.⁹ In addition, efficacy for L-97-1 as an antisepsis treatment was shown in a rat model of CLP, an animal model of polymicrobial septicemia, endo-toxemia and ALI.¹⁴ In this CLP model of septicemia, L-97-1 increased 7-d survival rates from 17% for untreated septic controls and 25% in animals given antibiotics alone, to 30–40% with L-97-1 alone, and to 50–70% with L-97-1 plus antibiotics.

Additional information suggesting that the A₁AR may be an important molecular target for LPS comes from *in vitro* pharmacology assays for the A₁AR, including radioligand competition binding and functional assays. In *in vitro* competition binding studies, LPS from US Pharmacopeia (Rockville, MD, USA) had an affinity (K_i) of 2.4 μ g/ml for rat A₁ARs stably expressed in Sf9 cells and labeled with [³H]-DPCPX (unpublished data, Constance N. Wilson). Previously, it was reported that in competition binding studies using membranes prepared from human PAECs, LPS from *Escherichia coli*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* displaced the binding of another high affinity A₁AR antagonist radioligand, [¹²⁵I] BWA844U (IC₅₀ = 195 ng/ml, 290 ng/ml, 602 ng/ml, and 693 ng/ml respectively).¹³

In an *in vitro* pharmacological functional assay, e.g. a [³⁵S] GTP γ S GTP binding assay to measure A₁AR agonist-mediated activation of G proteins, using membranes prepared from Chinese hamster ovary (CHO) cells stably expressing the rat A₁AR, both LPS and N⁶-

cyclopentyladenosine (CPA), a selective A₁AR agonist, activated G proteins. This activation by both LPS and CPA was significantly blocked by the A₁AR antagonist, DPCPX, as well as by pertussis toxin, an inhibitor of Gi/o protein (unpublished data, Constance N. Wilson). These results suggest that LPS functions as an A₁AR agonist to activate A₁ARs coupled to a Gi/o protein. These results considered with a previous report that LPS activation of A₁ARs on human PAECs induces the release of cytotoxic substances, thromboxane and IL-6, suggest that LPS induces ALI by activation of A₁ARs. Collectively, the results from the *in vitro* studies taken with those from the *in vivo* studies that A₁AR antagonists block LPS-induced and *Y. pestis*-induced ALI and increase survival in two different animal models of sepsis, CLP-induced polymicrobial sepsis and *Y. pestis*-induced Gram-negative sepsis as reported in the current study and in previous reports, suggest that the A₁AR is an important molecular target for LPS.

In the current study, plasma levels of L-97-1 for a single 8-h infusion of L-97-1 (10 mg/kg/h, IV) in normal, uninfected animals peaked at a concentration of $3.66 \pm 1.06 \mu\text{g/ml}$ at the 4-h midpoint of the infusion. During the 3-d 8 h infusion, trough plasma levels of L-97-1 never declined below $0.38 \mu\text{g/ml}$. These plasma levels correlate with L-97-1 concentrations of $6 \mu\text{M}$ and $0.6 \mu\text{M}$ respectively. In *in vitro* pharmacologic competition binding studies, L-97-1 binds to the rat A₁AR stably expressed in Sf9 cells with an affinity of 550 nM (corresponding to 326 ng/ml) and to the rat A₁AR stably expressed in CHO cells with an affinity of $2.8 \mu\text{M}$ (corresponding to 1358 ng/ml; unpublished data, Constance N. Wilson). Although the affinity of *Y. pestis* LPS for the rat A₁AR has not been determined and LPS plasma levels were not measured in the current study, based on the affinity of LPS and L-97-1 for the rat A₁AR, the plasma concentrations of L-97-1 in the present study should have been sufficient to effectively compete with LPS for binding to A₁ARs. Although it is not known if plasma concentrations of the agonist, LPS, or the antagonist, L-97-1 in the current study, were sufficient to saturate A₁ARs, it would appear from the leveling off of the survival rate at 70% for the highest doses of L-97-1 that A₁ARs were saturated with L-97-1.

In addition to the improved survival and reduced ALI achieved by using L-97-1 as an adjunctive therapy to antibiotics in a rat CLP sepsis model and in this study of pneumonic plague, L-97-1 has shown efficacy in an animal model of asthma, where it blocked allergic airway responses, hyper-reactivity and inflammation.^{44,45} Others have reported that A₁AR antagonists block ischemia-reperfusion injury of the heart, lung, liver, and pancreas.³³ It is worth noting, however, that as opposed to a pro-inflammatory effect of A₁AR activation, other reports have suggested an anti-inflammatory, protective effect for the A₁AR.³³ Based on the findings in one of these reports, the use of A₁AR antagonists in sepsis is not supported. In that report, the survival rate of A₁AR knockout (KO) mice with CLP-induced sepsis was lower than that for the wild-type mice with CLP. In the same report, wild-type mice with CLP-induced sepsis treated with the A₁AR antagonist, DPCPX, had a lower survival rate than the CLP controls.

There are a number of possible explanations to clarify the differences between these studies in mice with CLP sepsis versus the current studies in rats. Firstly, genetically manipulated animals may have compensatory expression of other proteins that alter the phenotypes of cells and organs. These altered phenotypes may play a significant role in the organ injuries seen in these KO models. Secondly, although at low concentrations DPCPX has high affinity for the A₁AR and serves as an A₁AR antagonist, at higher concentrations, DPCPX may function as an inverse agonist for the A₁AR.⁴⁶ In addition, at higher concentrations, DPCPX is not selective for the A₁AR and may block the anti-inflammatory effects of the Gs coupled A_{2b}AR.³³ A detailed discussion of the proinflammatory versus the anti-inflammatory effects of A₁AR activation is provided in a recent publication.³³

In summary, the findings in the current study support efficacy for L-97-1 as a post-exposure MCM to cipro for the treatment of *Y. pestis*-induced sepsis. The mechanism of action for the beneficial effects of L-97-1 as an adjunctive therapy to cipro on survival, ALI and shock in the rat model of pneumonic plague in the current study is not known at this time. Based on reports that LPS is an important virulence factor for *Y. pestis*, that LPS binds to and activates A₁ARs, and that A₁AR antagonists block LPS-induced ALI and improve survival following CLP, it is possible that L-97-1 is blocking activation of A₁ARs by LPS to produce ALI and septic shock in this animal model of *Y. pestis*-induced sepsis. The role of LPS in *Y. pestis*-induced ALI and septic shock in this rat model of pneumonic plague, as well as other possible mechanisms of action to explain the efficacy of L-97-1 as an adjunctive therapy to cipro in this animal model of sepsis, are areas for future investigations. Furthermore, it is important to note that the host response to a more virulent strain of *Y. pestis*, such as the parent wildtype CO92 strain from which the CO99 pCD1⁺/Δpgm *Y. pestis* strain used for the current studies was derived, may differ.⁴⁷ Efficacy for L-97-1 as a post-exposure MCM for *Y. pestis* CO92-induced pneumonic plague and sepsis is yet to be determined, an area for future investigation, and a requirement to advance this promising anti-sepsis therapeutic as a MCM for plague sepsis in humans.

Acknowledgments

The authors are indebted to Dr Susan C. Straley at the University of Kentucky School of Medicine for her gift of the CO99 pCD1⁺/Δpgm used herein. At Saint Louis University, Dr Zhoumou Chen provided essential surgical skill and numerous other contributions, as did Colin Chen, Andrew Lechner III, and Megan Walker-Wohlschlagler. This work was principally supported by SBIR Phase I/Biodefense Grant R43 AI-069636 from the National Institute of Allergy and Infectious Disease (NIAID), C. N. Wilson, Principal Investigator. Additional support was provided by NIAID Grant R21 AI-059099 to A. J. Lechner, and by institutional funds to G. M. Matuschak and the Division of Pulmonary, Critical Care & Sleep Medicine of the Department of Internal Medicine.

References

1. Perry RD, Fetherston JD. *Yersinia pestis*—etiologic agent of plague. Clin Microbiol Rev. 1997; 10:35–66. [PubMed: 8993858]
2. World Health Organization. Human plague in 2002 and 2003. Wkly Epidemiol Rec. 2004; 79:301–306. [PubMed: 15369044]
3. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Plague as a biological weapon: Medical and public health management. JAMA. 2000; 283:2281–2290. [PubMed: 10807389]
4. Inglesby TV, Grossman R, O'Toole T. A plague on your city: observations from TOPOFF. Clin Infect Dis. 2001; 32:436–445. [PubMed: 11170952]
5. Gradon JD. Plague Pneumonia. Curr Infect Dis Rep. 2002; 4:244–248. [PubMed: 12015918]
6. Anisimov AP, Amoako KK. Treatment of plague: Promising alternatives to antibiotics. J Med Microbiol. 2006; 55:1461–1475. [PubMed: 17030904]
7. Bruneteau M, Minka S. Lipopolysaccharides of bacterial pathogens from the genus *Yersinia*: A mini-review. Biochimie. 2003; 85:145–152. [PubMed: 12765784]
8. Dentovskaya SV, Bakhteeva IV, Titareva GM, Shaikhutdinova RZ, Kondakova AN, Bystrova OV, et al. Structural diversity and endotoxic activity of the lipopolysaccharide of *Yersinia pestis*. Biochem. 2008; 73:192–199. [PubMed: 18298376]
9. Neely CF, Jin J, Keith IM. A₁-adenosine receptor antagonists block endotoxin-induced lung injury. Am J Physiol. 1997; 272:L353–L361. [PubMed: 9124387]
10. Agar SL, Sha J, Foltz SM, Erova TE, Walberg KG, Parham TE, et al. Characterization of a mouse model of plague after aerosolization of *Yersinia pestis* CO92. Microbiol. 2008; 154:1939–1948.
11. Welkos S, Pitt MLM, Martinez M, Friedlander A, Vogel P, Tammariello R. Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of *Yersinia pestis* in non-human primate and mouse models of pneumonic plague. Vaccine. 2000; 20:2206–2214. [PubMed: 12009274]

12. Guarner J, Shieh W-J, Greer PW, Gabastou J-M, Chu M, Hayes E, et al. Immunohistochemical detection of *Yersinia pestis* in formalin-fixed, paraffin-embedded tissue. *Am J Clin Pathol.* 2002; 117:205–209. [PubMed: 11863216]
13. Wilson CN, Batra VK. Lipopolysaccharide binds to and activates A(1) adenosine receptors on human pulmonary artery endothelial cells. *J Endotoxin Res.* 2002; 8:263–271. [PubMed: 12230916]
14. Wilson CN, Vance CO, Goto M. A₁ adenosine receptor antagonist, L-97-1, improves survival and acute lung injury following cecal ligation and perforation. *J Leukocyte Biol.* 2006; (Suppl. 2006): 62.
15. Doll JM, Zeitz PS, Ettestad P, Bucholtz L, Davis T, Gage K. Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. *Am J Trop Med Hyg.* 1994; 51:109–114. [PubMed: 8059908]
16. Straley SC, Bowmer WS. Virulence genes regulated at the transcriptional level by Ca²⁺ in *Yersinia pestis* include structural genes for outer membrane proteins. *Infect Immun.* 1986; 51:445–454. [PubMed: 3002984]
17. Straley SC, Cibull ML. Differential clearance and host-pathogen interactions of YopE⁻ and YopK⁻/YopL⁻ *Y. pestis* in BALB/c mice. *Infect Immun.* 1989; 57:1200–1210. [PubMed: 2925246]
18. Doyle TM, Matuschak GM, Lechner AJ. Septic shock and non-pulmonary organ dysfunction in pneumonic plague: The role of *Y. pestis* pCD1⁻ vs. pgm⁻ virulence factors. *Crit Care Med.* 2010; 38:1574–1583. [PubMed: 20400901]
19. Matuschak GM, Doyle TM, Lechner AJ. *Yersinia pestis* KIM6⁺-induced lung pathobiology and systemic cytokine production. *Crit Care Med.* 2004; 32:A479.
20. Lechner AJ, Doyle TM, Chen Z, Matuschak GM. Bacterial dissemination and systemic tissue inflammation following intratracheal infection of rats with *Yersinia pestis*. *FASEB J.* 2006; 20:1381–1382.
21. Lechner AJ, Ryerse JS, Matuschak GM. Acute lung injury during bacterial or fungal sepsis. *Microsc Res Tech.* 1993; 26:444–456. [PubMed: 8286790]
22. Lechner AJ, Velasquez A, Knudsen KR, Johanns CA, Tracy TF, Matuschak GM. Cholestatic liver injury increases circulating TNF- α and IL-6 and mortality after *E. coli* endotoxemia. *Am J Resp Crit Care Med.* 1998; 157:1550–1558. [PubMed: 9603137]
23. Prentice MB, Rahalison L. Plague. *Lancet.* 2007; 369:1196–1207. [PubMed: 17416264]
24. Hepburn MJ, Purcell BK, Paragas J. Pathogenesis and sepsis caused by organisms potentially utilized as biologic weapons: Opportunities for targeted intervention. *Curr Drug Targets.* 2007; 8:519–532. [PubMed: 17430123]
25. Lathem WW, Crosby SD, Miller VL, Goldman WE. Progression of primary pneumonic plague: A mouse model of infection, pathology, and bacterial transcriptional activity. *Proc Nat Acad Sci.* 2005; 102:17786–17791. [PubMed: 16306265]
26. Van Amersfoort ES, Van Berkel TJC, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. *Clin Microbiol Rev.* 2003; 16:379–414. [PubMed: 12857774]
27. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on course of inflammation and outcome in sepsis and meningitis. *Clin Micro Rev.* 2002; 15:95–110. [PubMed: 11781269]
28. Cornelius CA, Quenee LE, Overheim KA, Koster F, Brasel TL, Elli D, et al. Immunization with recombinant V10 protects *Cynomolgus* Macaques from lethal pneumonic plague. *Infect Immun.* 2008; 76:5588–5597. [PubMed: 18794281]
29. Anderson DM, Ciletti NA, Lee-Lewis H, Elli D, Segal J, DeBord KL, et al. Pneumonic plague pathogenesis and immunity in Brown Norway rats. *Am J Pathol.* 2009; 174:910–921. [PubMed: 19164505]
30. Lechner AJ, Doyle TM, Ryerse JS, Matuschak GM. Alveolar macrophages fail to kill avirulent *Yersinia pestis* despite rapid phagocytosis and induced production of TNF- α and IL-1 β . *Am J Respir Crit Care Med.* 2006; 169:A232.
31. Lawson JN, Lyons CR, Johnston SA. Expression profiling of *Yersinia pestis* during mouse pulmonary infection. *DNA Cell Biol.* 2006; 25:608–616. [PubMed: 17132091]

32. Benner GE, Andrews GP, Byrne R, Strachan SD, Sample AK, Heath DG, et al. Immune response to *Yersinia* outer proteins and other *Y. pestis* antigens after experimental plague infection in mice. *Infect Immun*. 1999; 67:1922–1928. [PubMed: 10085037]
33. Blackburn, MR.; Vance, CO.; Morschl, E.; Wilson, CN. Adenosine receptors and inflammation.. In: Wilson, CN.; Mustafa, SJ., editors. Adenosine receptors in health and disease. Handbook of experimental pharmacology. Springer-Verlag; Heidelberg: 2009. p. 215-269.
34. Funakoshi H, Zacharia LC, Zhonghua T, Zhang J, Lee LL, Good JC, et al. A₁ adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. *Circulation*. 2007; 115:2307–2315. [PubMed: 17438146]
35. Mustafa, SJ.; Morrison, RR.; Teng, B.; Pelleg, A. Adenosine receptors and the heart: Role in regulation of coronary blood flow and cardiac electrophysiology.. In: Wilson, CN.; Mustafa, SJ., editors. Adenosine receptors in health and disease. Handbook of experimental pharmacology. Springer-Verlag; Heidelberg: 2009. p. 161-188.
36. Neely CF, Haile DM, Cahill BE, Kadowitz PJ. Adenosine and adenosine 5'-triphosphate produce vasoconstriction in the feline pulmonary vascular bed by different mechanisms. *J Pharmacol Exp Ther*. 1991; 258:753–761. [PubMed: 1832463]
37. Vallon, V.; Osswald, H. Adenosine receptors and the kidney.. In: Wilson, CN.; Mustafa, SJ., editors. Adenosine receptors in health and disease. Handbook of experimental pharmacology. Springer-Verlag; Heidelberg: 2009. p. 443-470.
38. Wilson, CN.; Nadeem, A.; Spina, D.; Brown, R.; Page, CP.; Mustafa, SJ. Adenosine receptors and asthma.. In: Wilson, CN.; Mustafa, SJ., editors. Adenosine receptors in health and disease. Handbook of experimental pharmacology. Springer-Verlag; Heidelberg: 2009. p. 329-362.
39. Martin C, Leone M, Viviani X, Ayem M-L, Guieu R. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. *Crit Care Med*. 2000; 28:3198–3202. [PubMed: 11008982]
40. Jhaveri KA, Reichensperger J, Toth LA, Sekino Y, Ramkumar V. Reduced basal and lipopolysaccharide-stimulated adenosine A₁ receptor expression in the brain of nuclear factor- κ B p50^{-/-} mice. *Neurosci*. 2007; 146:415–426.
41. Satoh A, Shimosegawa T, Satoh K, Ito H, Kohno Y, Masamune A, et al. Activation of adenosine A₁-receptor pathway induces edema formation in the pancreas of rats. *Gastroenterol*. 2000; 119:829–836.
42. Neely CF, Keith I. A₁ adenosine receptor antagonists block ischemia-reperfusion injury of the lung. *Am J Physiol*. 1995; 268:L1036–L1046. [PubMed: 7611426]
43. Factor P, Mutlu GM, Chen L, Mohameed J, Akhmedov AT, Meng FJ, et al. Adenosine regulation of alveolar fluid clearance. *Proc Natl Acad Sci*. 2007; 104:4083–4088. [PubMed: 17360481]
44. Obiefuna PC, Batra VK, Nadeem A, Borron P, Wilson CN, Mustafa SJ. A Novel A₁ adenosine receptor antagonist, L-97-1, [3-[2-(4-Aminophenyl)-ethyl]-8-benzyl-7-{2-[ethyl-(2-hydroxyethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma. *J Pharmacol Exp Ther*. 2005; 315:329–336. [PubMed: 16020631]
45. Nadeem A, Obiefuna PC, Wilson CN, Mustafa SJ. A₁ adenosine receptor antagonist versus montelukast on airway reactivity and inflammation. *Eur J Pharmacol*. 2006; 551:116–124. [PubMed: 17027749]
46. Dhalla AK, Shryock JC, Shreenivas R, Belardinelli L. Pharmacology and therapeutic application of A₁ adenosine receptor ligands. *Curr Top Med Chem*. 2003; 3:369–385. [PubMed: 12570756]
47. Lawrenz MB. Model systems to study plague pathogenesis and develop new therapeutics. *Front Microbiol*. 2010; 1:1–9. [PubMed: 21687722]

Figure 1.

Six-day survival curves in catheterized rats following intratracheal (i.t.) infection with *Y. pestis* (strain CO99, 1×10^8 CFU/animal) at $t = 0$ h. Study groups shown here include those described in the 'Materials and methods' that received treatments starting at $t = 72$ h consisting of: no interventions; ciprofloxacin (cipro; 10 mg/kg, b.i.d. $\times 3$ d, IV) plus sterile water (H_2O , 0.5 ml/h $\times 8$ h/d $\times 3$ d, IV); H_2O (0.5 ml, b.i.d. $\times 3$ d, IV) plus L-97-1 (10 mg/kg/h $\times 8$ h/d $\times 3$ d, IV); or cipro (10 mg/kg, b.i.d. $\times 3$ d, IV) plus L-97-1 (1, 5, 10, or 20 mg/kg/h $\times 8$ h/d $\times 3$ d, IV).

Figure 2.

Lung edema scored as described in the 'Materials and methods' for untreated animals killed by protocol 72 h following *Y. pestis* infection (strain CO99, 1×10^8 CFU/animal), as well as the 6-d survivors in Figure 1, in which no intervention occurred or treatments started at $t = 72$ h (see Figure 1 for additional details about treatments, doses, and routes of administration). Edema was scored to reflect fluid visible in either the interstitial or alveolar compartments, on a scale of none or normal (0), mild (1), moderate (2), or severe (3). ^ ($P < 0.05$), ^^ ($P < 0.01$) compared to *Y. pestis*, no treatment (144 h); + ($P < 0.05$), ++ ($P < 0.01$) compared to *Y. pestis*, no treatment (72 hr); # ($P < 0.05$), ### ($P < 0.001$) compared to *Y. pestis*, ciprofloxacin (cipro; 72 h). Group-to-group comparisons were made using Student's t test for unpaired data.

Figure 3.

Lung LII as described in the 'Materials and methods' for untreated animals killed by protocol 72 h following *Y. pestis* infection (strain CO99, 1×10^8 CFU/animal), and for the groups of 6-d survivors in Figure 1, in which no intervention occurred or treatments started at $t = 72$ h (see Figure 1 for additional details on treatments, doses, and routes of administration). The LII was scored as normal (0), mild (1), moderate (2), or severe (3), and reflected both the extent of alveolar and interstitial leukocyte involvement and the degree to which resident alveolar macrophages were displaced or outnumbered by neutrophils and lymphocytes not visible in the alveolar airspaces or lung interstitium of uninfected surgical controls. ^ ($P < 0.05$) compared to *Y. pestis*, no treatment (144 h); + ($P < 0.05$), +++ ($P < 0.001$) compared to *Y. pestis*, no treatment (72 h). Group-to-group comparisons were made using Student's *t* test for unpaired data.

Figure 4.

Aggregate or overall lung injury score (alveolar and interstitial edema, hemorrhage, and LII scores) as described in the 'Materials and methods' for untreated animals killed by protocol 72 h following *Y. pestis* infection (strain CO99, 1×10^8 CFU/animal), and for groups of 6-d survivors in Figure 1, in which either no intervention occurred or treatments started at $t = 72$ h (see Figure 1 for additional details about treatments, doses, and routes of administration). A maximal score of 9 would reflect a ranking of 'severe' for that lung specimen across all categories of injuries. [^] ($P < 0.05$) compared to *Y. pestis*, no treatment (144 h); ⁺ ($P < 0.05$), ⁺⁺ ($P < 0.01$), ⁺⁺⁺ ($P < 0.001$) compared to *Y. pestis*, no treatment (72 h); ^{##} ($P < 0.001$) compared to *Y. pestis*, cipro (72 h). Group-to-group comparisons were made using Student's t test for unpaired data.

Figure 5.

Representative lung tissue (hematoxylin and eosin, 100 X) from an untreated animal necropsied by protocol at $t = 72$ h after infection with viable *Y. pestis* (strain CO99, 1×10^8 CFU/animal). It was chosen randomly from among 10 untreated rats evaluated at 72 h, whose group lung injury scores are shown in the center of each of the upper histograms in Figures 2–4. Note that most alveoli are filled with neutrophils, lymphocytes, alveolar macrophages and fibrinous exudate. Such lungs reflected the presumptive baseline for infected animals whose various treatments began at $t = 72$ h.

Figure 6.

Representative lung tissue (hematoxylin and eosin, 100 X) from a *Y. pestis*-infected animal that survived to $t = 6$ d, after being treated for 3 d with cipro 10 mg/kg, b.i.d., IV) plus sterile H₂O (0.5 ml/h $\times$ 8 h, IV) starting at $t = 72$ h. The image was chosen randomly from those for only 5 such 6-d survivors among 18 rats in this treatment group (Table 2), and whose mean lung injury scores are shown as the 'cipro' group in Figures 2–4. Note the perivascular edema at the top and the extensive zone of leukocyte-rich infiltrates within alveolar airspaces, resembling lungs from an untreated rat at $t = 72$ h in Figure 5.

Figure 7.

Representative lung tissue (hematoxylin and eosin, 100 X) from a *Y. pestis*-infected animal that survived to t = 6 d, after being treated for 3 d with cipro 10 mg/kg, b.i.d., IV) plus L-97-1(10 mg/kg/h × 8 h/d, IV) starting at t = 72 h. The image was selected randomly from the 7 such 6-d survivors among 10 rats in this treatment group (Table 2), and whose mean lung injury scores are shown as the ‘cipro + L-97-1 (10 mg/kg)’ group in Figures 2–4. Note the clear air-filled alveolar airspaces and interstitium that were scored as ‘normal’ and considered indistinguishable from the lung tissue of uninfected surgical control animals, except for the slight cell-free peribronchiolar edema at left that was scored ‘mild’.

Table 1

Survival rates in rats after intratracheal infection with graded inocula of *Y. pestis* (strain CO99) at t = 0 h and left untreated through 6 d

CFU/animal	72-h Survival (%)	144-h Survival (%)
1×10^7	3/4 (75)	2/4 (50)
1×10^8	8/12 (67)	5/12 (42)
1×10^9	4/8 (50)	2/8 (25)

CFU, colony forming unit.

Table 2

Effect of treatment with cipro and without L-97-1 at different time points following intratracheal (i.t.) infection with *Y. pestis* CO99pgm- 1×10^8 CFU on survival

Treatment group (<i>n</i> = number of animals)	Treatment time post-i.t. infection (h)	Median survival time (h)	Survival (%)
No intervention (<i>n</i> = 15)	Not applicable	96	33
L-97-1 (10 mg/kg/h) (<i>n</i> = 11)	0 (immediate)	108	45
H ₂ O (<i>n</i> = 10)	0 (immediate)	108	40
L-97-1 (10 mg/kg/h) (<i>n</i> = 10)	6	120	40
H ₂ O (<i>n</i> = 10)	6	120, 144 [*]	50
Cipro (10 mg/kg b.i.d.) + H ₂ O (<i>n</i> = 10)	24	> 144	100
H ₂ O (<i>n</i> = 10)	24	100, 120 [*]	30
Cipro (10 mg/kg b.i.d.) + H ₂ O (<i>n</i> = 14)	48	> 144	64
Cipro (10 mg/kg b.i.d.) + L-97-1 (10 mg/kg/h) (<i>n</i> = 11)	48	> 144	55
H ₂ O (<i>n</i> = 9)	48	84	11
Cipro (10 mg/kg b.i.d.) + H ₂ O (<i>n</i> = 18)	72	84	28
L-97-1 (10 mg/kg/h) + H ₂ O (<i>n</i> = 10)	72	96	20
Cipro + L-97-1 (1 mg/kg/h) (<i>n</i> = 10)	72	> 144	60
Cipro + L-97-1 (5 mg/kg/h) (<i>n</i> = 10)	72	> 144	70
Cipro + L-97-1 (10 mg/kg/h) (<i>n</i> = 10)	72	> 144	70
Cipro + L-97-1 (20 mg/kg/h) (<i>n</i> = 13)	72	> 144	69
Cipro + L-97-1 (20 mg/kg b.i.d, oral) (<i>n</i> = 15)	72	> 144	60

* Actual survival times of the two rats on either side of the median point in a treatment subgroup containing an even number of animals.

Table 3

Effect of L-97-1 with and without cipro on lung edema at 6 d when treatment began at 72 h post-intratracheal (i.t.) infection with *Y. pestis* CO99pgm

Treatment group (n = number of animals)	Lung edema score ^a	P value ^b	Comparison treatment group
No treatment – 144 h (n = 4)	0.75 ± 0.48		
No treatment – 72 h ^c (n = 10)	3.10 ± 0.43	0.0088	No treatment – 144 h
Cipro + H ₂ O (n = 5)	2.40 ± 0.40	0.032	No treatment – 144 h
Cipro + L-97-1 (1 mg/kg/h) (n = 6)	1.17 ± 0.40	0.0095	No treatment – 72 h
Cipro + L-97-1 (5 mg/kg/h) (n = 7)	1.43 ± 0.30	0.0112	No treatment – 72 h
Cipro + L-97-1 (10 mg/kg/h) (n = 7)	1.00 ± 0.00	0.0011	No treatment – 72 h
Cipro + L-97-1 (10 mg/kg/h) (n = 7)	1.00 ± 0.00	0.0017	Cipro + H ₂ O
Cipro + L-97-1 (20 mg/kg/h) (n = 9)	1.11 ± 0.31	0.0019	No treatment – 72 h
Cipro + L-97-1 (20 mg/kg/h) (n = 9)	1.11 ± 0.31	0.0268	Cipro + H ₂ O

^a Using double-blind scoring method, lung edema was quantified histologically in at least 10 random high-powered fields per hematoxylin and eosin-stained sagittal lung section at 40X, 100X and 400X using a scale of 0 (normal), 1 (mild), 2 (moderate), or 3 (severe), and is expressed as mean ± SEM.

^b Lung edema scores were analyzed using Student's *t* test for unpaired data. The level of significance was set at $P < 0.05$. The data presented here correlate with that presented in Figure 2. Details for different group comparisons and *P* values are provided in Figure 2.

^c Animals from 72 h time-killed group; otherwise, all animals in all groups were survivors at 144 h.

Table 4

Effect of L-97-1 with and without cipro on lung leukocyte infiltration index (LII) at 6 d when treatment starts at 72 h post-intratracheal (i.t.) infection with *Y. pestis* CO99pgm

Treatment group (n = number of animals)	LII score ^a	P value ^b	Comparison treatment group
No treatment – 144 h (n = 4)	1.30 ± 0.12		
No treatment – 72 h ^c (n = 10)	1.75 ± 0.10	0.0258	No treatment – 144 h
Cipro + H ₂ O (n = 5)	1.25 ± 0.30	0.8936	No treatment – 144 h
Cipro + L-97-1 (1 mg/kg/h) (n = 6)	1.33 ± 0.26	0.0959	No treatment – 72 h
Cipro + L-97-1 (5 mg/kg/h) (n = 7)	1.04 ± 0.25	0.0102	No treatment – 72 h
Cipro + L-97-1 (10 mg/kg/h) (n = 7)	0.65 ± 0.09	< 0.0001	No treatment – 72 h
Cipro + L-97-1 (10 mg/kg/h) (n = 7)	0.65 ± 0.09	0.0536	Cipro + H ₂ O
Cipro + L-97-1 (20 mg/kg/h) (n = 9)	0.80 ± 0.12	< 0.0001	No treatment – 72 h
Cipro + L-97-1 (20 mg/kg/h) (n = 9)	0.80 ± 0.12	0.1225	Cipro + H ₂ O

^a Using double-blind scoring method, LII was quantified histologically in a total of 11 high powered fields for each hematoxylin and eosin-stained sagittal lung section independently selected by microscope stage coordinates at 400X using a scale of 0 (normal), 1 (mild), 2 (moderate) or 3 (severe), and is expressed as mean ± SEM.

^b Lung LII scores were analyzed using Student's *t* test for unpaired data. The level of significance was set at $P < 0.05$. The data presented here correlate with that presented in Figure 3. Details for different group comparisons and *P* values are provided Figure 3.

^c Animals from 72 h time-killed group; otherwise, all animals in all groups were survivors at 144 h.

Table 5

Effect of L-97-1 with and without cipro on aggregate lung injury score at 6 d when treatment began at 72 h post-intratracheal (i.t.) infection with *Y. pestis* CO99pgm

Treatment group (n = number of animals)	Lung score ^a	P value ^b	Comparison treatment group
No treatment – 144 h (n = 4)	2.55 ± 0.73		
No treatment – 72 h ^c (n = 10)	6.65 ± 0.84	0.0141	No treatment – 144 h
Cipro + H ₂ O (n = 5)	5.05 ± 1.02	0.1010	No treatment – 144 h
Cipro + L-97-1 (1 mg/kg/h) (n = 6)	2.83 ± 0.50	0.0052	No treatment – 72 h
Cipro + L-97-1 (5 mg/kg/h) (n = 7)	3.90 ± 0.87	0.0420	No treatment – 72 h
Cipro + L-97-1 (10 mg/kg/h) (n = 7)	2.22 ± 0.22	0.0006	No treatment – 72 h
Cipro + L-97-1 (10 mg/kg/h) (n = 7)	2.22 ± 0.22	0.0096	Cipro + H ₂ O
Cipro + L-97-1 (20 mg/kg/h) (n = 9)	2.91 ± 0.54	0.0019	No treatment – 72 h
Cipro + L-97-1 (20 mg/kg/h) (n = 9)	2.91 ± 0.54	0.0620	Cipro + H ₂ O

^a Using double-blind scoring method lung, (interstitial plus alveolar) edema, hemorrhage and LII were quantified histologically in at least 10 random high powered fields per hematoxylin and eosin-stained sagittal lung section using a scale of 0 (normal), 1 (mild), 2 (moderate), or 3 (severe). Total aggregate lung injury scores expressed as the sum of the individual injury scores for lung edema, hemorrhage and LII were determined and are expressed as mean ± SEM.

^b Aggregate lung injury scores were analyzed using Student's *t* test for unpaired data. The level of significance was set at $P < 0.05$. The data presented here correlate with that presented in Figure 4. Details for different group comparisons and *P* values are provided in Figure 4.

^c Animals from 72 h time-killed group; otherwise, all animals in all groups were survivors at 144 h.

Table 6

Effect of L-97-1 with and without cipro on physiologic measurements at 6 d when treatment began at 72 h post-intratracheal (i.t.) infection with *Y. pestis* CO99pgm

Treatment group	Lung W/D weight ratio (number of animals)	(A-a)PO ₂ (mmHg) (number of animals)	MAP (mmHg) (number of animals)
No intervention, 72 h ^a	4.77 ± 0.27 (9)	16.9 ± 9.5 (5)	134 ± 26 (5)
No intervention, 144 h	4.49 ± 0.74 (5)	29.8 ± 23.1 (5)	91 ± 20 (5) *
Cipro + H ₂ O	4.34 ± 0.58 (5)	10.7 ± 5.4 (5)	90 ± 18 (5) *
Cipro + L-97-1 (1 mg/kg/h)	4.66 ± 0.36 (6)	21.1 ± 3.4 (5)	119 ± 21 (6)
Cipro + L-97-1 (5 mg/kg/h)	4.97 ± 0.28 (5)	15.1 ± 9.4 (4)	120 ± 21 (7)
Cipro + L-97-1 (10 mg/kg/h)	4.92 ± 0.35 (7)	12.3 ± 10.0 (4)	112 ± 19 (5)
Cipro + L-97-1 (20 mg/kg/h)	4.75 ± 0.74 (6)	11.4 ± 6.3 (4)	120 ± 21 (4)

Lung W/D weight ratios, (A-a)PO₂, and MAPs were analyzed using mixed linear model analysis for differences within and among treatment groups over time.

W/D, wet-to-dry; MAP, mean arterial pressure.

^aMeasurements are from animals in 72 h time-killed group; otherwise, measurements are from survivors at 144 h.

* Indicates level of significance at $P < 0.05$ vs. no intervention group at $t = 72$ h.

Table 7

Plasma L-97-1 levels (ng/ml) during a single continuous 8-h infusion (10 mg/kg/h, IV) in normal, uninfected rats

Sample	1 min	30 min	1 h	2 h	4 h	8 h
Mean	17	7	1821	2323	3664	2505
SEM	± 6	± 3	± 332	± 532	± 1055	± 798

Data are presented as mean ± SEM, $n = 4$.

Peak and trough plasma levels (ng/ml) of L-97-1 during three consecutive daily 8-h infusions (10 mg/kg/h, IV) in normal, uninfected rats

Table 8

Sample	1 min	8 h	24 h	32 h	48 h	56 h
Mean	94	2861	950	1851	375	1218
SEM	± 33	± 1207	± 865	± 661	± 230	± 760

Data are presented as mean ± SEM, *n* = 5.